A novel label-free cell-based assay technology using biolayer interferometry von Verzijl, D., Riedl, T., Parren, P.W.H.I., Gerritsen, A.F.

Volltext

Carbamylation reduces the capacity of IgG for hexamerization and complement activation von Lubbers, R., Oostindie, S. C., Dijkstra, D. J., Parren, P. W. H. I., Verheul, M. K., Abendstein, L., Sharp, T. H., Ru, A., Janssen, G. M. C., Veelen, P. A., den Bremer, E. T. J., Bleijlevens, B., Kreuk, B.‐J., Beurskens, F. J., Trouw, L. A.

Volltext

Crystal Structure of a Neutralizing Human IgG against HIV-1: A Template for Vaccine Design von Saphire, Erica Ollmann, Paul W. H. I. Parren, Pantophlet, Ralph, Zwick, Michael B., Morris, Garrett M., Rudd, Pauline M., Dwek, Raymond A., Stanfield, Robyn L., Burton, Dennis R., Wilson, Ian A.

Volltext

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dep... von Kellner, C, Hallack, D, Glorius, P, Staudinger, M, Mohseni Nodehi, S, de Weers, M, van de Winkel, J G J, Parren, P W H I, Stauch, M, Valerius, T, Repp, R, Humpe, A, Gramatzki, M, Peipp, M

Volltext

Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro von Parren, P W, Marx, P A, Hessell, A J, Luckay, A, Harouse, J, Cheng-Mayer, C, Moore, J P, Burton, D R

Volltext

CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma Cells von Peipp, M., Wesch, D., Oberg, H.‐H., Lutz, S., Muskulus, A., Winkel, J. G. J., Parren, P. W. H. I., Burger, R., Humpe, A., Kabelitz, D., Gramatzki, M., Kellner, C.

Volltext

Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 von Zwick, M B, Labrijn, A F, Wang, M, Spenlehauer, C, Saphire, E O, Binley, J M, Moore, J P, Stiegler, G, Katinger, H, Burton, D R, Parren, P W

Volltext

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells von Glorius, P, Baerenwaldt, A, Kellner, C, Staudinger, M, Dechant, M, Stauch, M, Beurskens, F J, Parren, P W H I, Winkel, J G J van de, Valerius, T, Humpe, A, Repp, R, Gramatzki, M, Nimmerjahn, F, Peipp, M

Volltext

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies von van der Veer, M S, de Weers, M, van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M, Mutis, T

Volltext

The pristine rain forest? Remnants of historical human impacts on current tree species composition and diversity von van Gemerden, Barend S., Olff, Han, Parren, Marc P.E., Bongers, Frans

Volltext

Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development von Kellner, C., Bleeker, W.K., Lammerts van Bueren, J.J., Staudinger, M., Klausz, K., Derer, S., Glorius, P., Muskulus, A., de Goeij, B.E.C.G., van de Winkel, J.G.J., Parren, P.W.H.I., Valerius, T., Gramatzki, M., Peipp, M.

Volltext

Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 von Hezareh, M, Hessell, A J, Jensen, R C, van de Winkel, J G, Parren, P W

Volltext

Recruitment of lianas into logging gaps and the effects of pre-harvest climber cutting in a lowland forest in Cameroon von Schnitzer, Stefan A, Parren, Marc P.E, Bongers, Frans

Volltext

Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies von Zwick, M B, Wang, M, Poignard, P, Stiegler, G, Katinger, H, Burton, D R, Parren, P W

Volltext

The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity von Parren, P W, Moore, J P, Burton, D R, Sattentau, Q J

Volltext

P1463: PHASE I DOSE ESCALATION OF LAVA‐051, A NOVEL BISPECIFIC GAMMA‐DELTA T‐CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES von Broijl, A., Donk, N., Bosch, F., Mateos, M. V., Rodriguez‐Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., Vliet, H., Kater, A.

Volltext

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development von Moore, J P, Parren, P W, Burton, D R

Volltext

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy von Da Roit, Fabio, Engelberts, Patrick J, Taylor, Ronald P, Breij, Esther C W, Gritti, Giuseppe, Rambaldi, Alessandro, Introna, Martino, Parren, Paul W H I, Beurskens, Frank J, Golay, Josée

Volltext

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab von VAN DER VEER, Michael S, DE WEERS, Michel, VAN KESSEL, Berris, BAKKER, Joost M, WITTEBOL, Shulamiet, PARREN, Paul W. H. I, LOKHORST, Henk M, MUTIS, Tuna

Volltext

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma von Drent, Esther, Groen, Richard W J, Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna

Volltext